A number of other analysts also recently issued reports on the company. Leerink Swann started coverage on Inflarx in a research note on Monday. They issued an “outperform” rating on the stock. J P Morgan Chase & Co started coverage on Inflarx in a research note on Monday. They issued an “overweight” rating on the stock.
Shares of Inflarx (NASDAQ IFRX) opened at $20.88 on Monday. Inflarx has a 12 month low of $14.47 and a 12 month high of $22.48.
ILLEGAL ACTIVITY WARNING: This piece of content was posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.com-unik.info/2017/12/04/inflarx-ifrx-now-covered-by-bmo-capital-markets.html.
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company’s primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases.
What are top analysts saying about Inflarx NV? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Inflarx NV and related companies.